

---

*primary studies - published RCT*

## **Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial.**

**Code:** PM22266895

**Year:** 2012 **Date:** 2012

**Author:** Robinson P

### **Study design (if review, criteria of inclusion for studies)**

international double blind, cross-over trial

### **Participants**

63 subjects with CF

### **Interventions**

either placebo or 500 mg oral clarithromycin twice daily for 5 months, with a 1-month wash-out.

### **Outcome measures**

The primary efficacy end point was the change in lung function (FEV<sub>1</sub>) and FVC) during the clarithromycin treatment period compared to placebo treatment. Secondary efficacy end points included quality of life, number of pulmonary exacerbations, height and weight, sputum inflammatory mediator content, sputum transportability and surface properties, bacterial flora, nasal potential difference, and breath condensate.

### **Main results**

No significant difference in either the primary efficacy end point or any secondary end point was seen during the period of clarithromycin treatment compared to those seen during placebo administration.

### **Authors' conclusions**

clarithromycin is not effective in treating CF lung disease.

<http://dx.doi.org/10.1002/ppul.21613>

### **See also**

Pediatr Pulmonol. 2012 Jun;47(6):551-7. doi: 10.1002/ppul.21613. Epub 2012 Jan 20.

### **Keywords**

Anti-Bacterial Agents; Clarithromycin; Macrolides; pharmacological\_intervention; Bacterial Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Infection;